NCT05486182View on ClinicalTrials.gov

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

April 18, 2025

Study Completion Date

January 31, 2026

Conditions
Metastatic Breast Cancer
Interventions
DRUG

18F Fluoroestradiol Radiopharmaceutical with PET/CT

Administration of one dose of 18F FES for PET/CT imaging

Trial Locations (11)

21079

CGFL, Dijon

31059

Institut Claudius Regaud Centre de Lutte Contre le Cancer, Toulouse

34298

Institut du Cancer de Montpellier, Montpellier

38700

CHU Grenoble Alpes, La Tronche

69008

Centre Léon Bérard, Lyon

75020

Hôpital Tenon, Paris

75248

Institut Curie, Paris

87000

CHU de Limoges - Dupuytren, Limoges

92200

Hôpital Américain de Paris, Neuilly-sur-Seine

92210

Institut Curie, Saint-Cloud

06189

Centre Antoine Lacassagne, Nice

Sponsors

Lead Sponsor

GE Healthcare

Collaborators (2)

Simbec-Orion Group
Keosys
All Listed Sponsors
collaborator

Simbec-Orion Group

INDUSTRY

collaborator

Keosys

UNKNOWN

lead

GE Healthcare

INDUSTRY